Omnicell OMCL underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table summarizes their recent ratings, shedding light ...

Omnicell, Inc. (Nasdaq: OMCL) (“Omnicell” or the “Company”), a leader in transforming the pharmacy and nursing care delivery model, today announced that Perry A. Genova, PhD, will join the ...

Omnicell (NASDAQ:OMCL – Get Free Report) had its price objective cut by stock analysts at JPMorgan Chase & Co. from $44.00 to $36.00 in a research report issued to clients and investors on ...